Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7640658 | 1.00 | MAPT (0.47) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL9394257 | 0.86 | SLC5A2 (0.50) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL16098645 | 0.86 | SLC5A2 (0.50) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL16781797 | 0.85 | MAPT (0.51) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL31685622 | 0.85 | MAPT (0.51) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL7764746 | 0.85 | MAPT (0.51) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL5903974 | 0.84 | PYGM (0.49) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL5903970 | 0.84 | PYGM (0.49) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL9060208 | 0.84 | PYGM (0.58) | MAPTCDAPYGMSLC28A1SLC28A2 | |
| SCHEMBL9060238 | 0.84 | PYGM (0.58) | MAPTCDAPYGMSLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328904-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2019-10-31 | — | — | US | claimed |
| WO-2024226784-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4423288-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | GenVivo, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076180-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3923967-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | Ignite Immunotherapy, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165730-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | Ignite Immunotherapy, Inc. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20190328904-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2019-10-31 | — | — | US | disclosed |
| CN-105246337-B | Thymidine Kinase Diagnostic Assays for Gene Therapy Applications | 吉恩维沃公司 | 2019-02-15 | — | — | CN | disclosed |
| US-20160310621-A1 | IMAGING PROBES, FORMULATIONS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-27 | — | — | US | disclosed |
| EP-2967078-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Epeius Biotechnologies Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970945-A2 | IMPROVED THYMIDINE KINASE GENE | Epeius Biotechnologies Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014153205-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153258-A2 | IMPROVED THYMIDINE KINASE GENE | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2419135-A1 | COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2316031-A2 | IL-8 BIOMARKER FOR MONITORING CANCER TREATMENT. | Schering Corporation (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010124009-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2212432-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | Schering Corporation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010021978-A2 | IL-8 BIOMARKER | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009055343-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-5053215-A | Phosphorylated by thymidine kinase in cells to produce a nondiffusing derivative and testing; viricides; herpes simplex virus | UNIVERSITY OF FLORIDA (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310621-A1 | IMAGING PROBES, FORMULATIONS, AND USES THEREOF | PPIP5K2, SOST, PTH1R | MAPT 3721/4885CDA 3200/4885PYGM 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.